Anticoagulants occupy a unique niche on the global bestselling drugs ranking.
Unaffected by sudden pandemics or short-lived market trends, they have long secured a core position in the global pharmaceutical market driven by rigid clinical demand.
In 2025, apixaban ranked sixth globally with $14.4 billion in worldwide sales, earning its title as the undisputed "King of Anticoagulants".
This sales figure not only surpassed blockbuster oncology drugs such as Opdivo and daratumumab, but also exceeded popular chronic disease medications like dapagliflozin.
Beneath this prosperity, however, patents are expiring, and the billion-dollar era of the "xaban" class is drawing to a close. Yet the anticoagulant sector will not halt its progress: a new generation of blockbuster drugs is on the horizon.

/ 01 /
An Unmatched Commercial Logic
The enormous size of the anticoagulant market is hardly surprising.
As the name suggests, antithrombotic drugs inhibit thrombus formation, promote thrombolysis, or prevent thrombus extension, thereby preventing and treating thromboembolic diseases.
The core value of these drugs lies in blocking the life threatening risks caused by blood clots. Stroke prevention in atrial fibrillation (AF) patients represents one of the most representative and urgent clinical scenarios.
For AF patients, thrombus prevention is a life saving necessity. During AF episodes, the atria fail to contract normally, causing blood stasis in the left atrial appendage and a high risk of clot formation. Once a clot dislodges and travels to the brain via the bloodstream, it triggers an ischemic stroke.
Data show that AF patients face five times the stroke risk of the general population, and such strokes carry far higher disability and mortality rates than other types. Consequently, anticoagulation has become the only effective method for stroke prevention in AF patients, with no alternative available.
More importantly, AF is a typical age related disease, and its patient pool is expanding alongside population aging: Prevalence reaches 5%–9% among people over 65; it exceeds 30% among those over 80.
Meanwhile, many previously asymptomatic AF patients went undiagnosed due to limited detection tools. With the widespread use of ECG and Holter monitoring, AF diagnosis rates are rising by 8%–10% annually, bringing more potential patients into treatment and further expanding the anticoagulant user base.
In addition to a large patient population, AF is a chronic, lifelong condition with no cure. Once patients meet anticoagulation criteria, they require long term or even lifelong therapy—there is no such thing as "recovery and discontinuation". This chronic use profile provides stable, sustained demand for anticoagulants.
Furthermore, anticoagulants are used far beyond AF related stroke prevention, greatly boosting market size: Orthopedics: Routine prophylaxis for venous thromboembolism (VTE) after knee or hip replacement, where prolonged immobility raises clot risk. Cardiology: Secondary prevention in patients with myocardial infarction or ischemic stroke, and prevention of ischemic complications in acute coronary syndrome (ACS).

In summary, the core demand driven by AF stroke prevention—large patient base, high necessity, long treatment duration—combined with widespread use across orthopedic, coronary, and other settings, creates powerful market momentum. Together, they have built a large, long prospering anticoagulant market.

/ 02 /
Demand for Safer, More Convenient Iteration
From the perspective of anticoagulant application scenarios, patient medication adherence is an indispensable key factor. Only when patients take the drug regularly over the long term can market demand be continuously realized, which also drives the ongoing iteration and upgrading of anticoagulants.
This iteration took a historic step forward with the approval of warfarin.
As the first oral anticoagulant, warfarin exerted a significant anticoagulant effect, reducing the incidence of stroke by 64% in patients with atrial fibrillation, well matching the core demand for long term medication. However, warfarin is far from perfect: it carries a severe and potentially fatal bleeding risk, has an unpredictable pharmacokinetic profile, and interacts with numerous drugs and foods, requiring frequent INR(International Normalized Ratio) monitoring. These shortcomings led to low acceptance and poor patient adherence in clinical practice, leaving substantial room for improvement.
The pursuit of safer and more convenient drugs has always been a core clinical and market demand.
The year 2008 marked another historic milestone in anticoagulant development: rivaroxaban, the first oral FXa inhibitor developed by Bayer, was approved. It not only validated the core value of the FXa target in anticoagulation but also broke the long standing monopoly of warfarin.
Nevertheless, the once daily dosing of rivaroxaban caused large peak trough fluctuations in plasma concentration, and bleeding risks remained in specific populations, creating an opportunity for subsequent drugs to overtake.
Apixaban, jointly developed by BMS and Pfizer, seized this opportunity. In the landmark ARISTOTLE trial, apixaban was proven superior to warfarin in efficacy for stroke prevention in atrial fibrillation, bleeding safety, and all cause mortality.
With its head to head victory over warfarin, apixaban quickly established its leading position in the anticoagulant market: Approved by the FDA in 2012 for reducing stroke and blood clot risk in patients with nonvalvular atrial fibrillation; Approved in 2014 for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), gradually covering multiple clinical scenarios of thromboembolic diseases.
It is fair to say that the prosperity of the anticoagulant market and drug iteration have been mutually reinforcing. The large patient population provides a broad market foundation for drug development, while continuous drug iteration—featuring fewer monitoring requirements, more stable anticoagulant effects, and lower adverse reaction rates—has greatly improved patient adherence. This has propelled the advancement of anticoagulant therapy, further stimulated market demand, and enabled the sustained expansion of the anticoagulant market.
/ 03 /
A New Window for Innovation and Upgrading
Even the best drugs have a life cycle, and the patent cliff is inevitable.
The “xaban” class is now facing patent expiration. The core patents of rivaroxaban expired in major markets such as the U.S. in July 2025, and the overseas core patents of apixaban will gradually expire between 2026 and 2028.
Generic competitors will not miss this huge anticoagulant market, and apixaban’s billion dollar era is coming to an end. Of course, this does not mean anticoagulants will lose their leading position, because innovation in mechanisms of action has never stopped.
Currently, FXI/FXIa inhibitors—as a new generation of anticoagulants—are expected to become the next mainstream.
Factor XI (FXI) is a critical component in the coagulation cascade activated by FXII in the intrinsic pathway, primarily responsible for activating FIX. FXIa is a plasma serine protease mainly synthesized by hepatocytes and circulates in its zymogen form (FXI).
Mechanistically, FXI/FXIa inhibitors differ fundamentally from traditional FXa inhibitors. The latter block the “main road” of the coagulation pathway, providing strong anticoagulant effects but also impairing normal physiological hemostasis. The latter block the “main road” of the coagulation pathway, providing strong anticoagulant effects but also impairing normal physiological hemostasis. Therefore, effectively preventing thrombosis while reducing bleeding risk remains a major unmet clinical need.
In contrast, FXI/FXIa inhibitors are designed to specifically suppress the formation, stabilization, and propagation of pathological thrombi, while preserving the normal hemostatic function required to respond to traumatic bleeding.

Theoretically, they therefore offer superior safety and can significantly reduce the risk of major bleeding and other severe hemorrhagic events.
Although no FXI/FXIa inhibitor has yet been approved, major pharmaceutical companies have already laid out extensive pipelines, with multiple FXI/FXIa targeted innovative drugs worldwide entering late stage clinical development.

A new round of restructuring in the anticoagulant field may be about to begin.